Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

2/6/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GILD alert in real time by email

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206319017/en/

Get the next $GILD alert in real time by email

Date	Price Target	Rating	Analyst
11/15/2024	$110.00	Outperform	Wolfe Research
11/14/2024	$125.00	Buy	Citigroup
11/8/2024		Buy → Hold	Maxim Group
10/21/2024	$74.00 → $96.00	Market Perform → Outperform	Leerink Partners
10/17/2024	$105.00	Outperform	Bernstein
10/7/2024	$78.00 → $100.00	Equal Weight → Overweight	Wells Fargo
7/8/2024	$93.00	Mkt Perform → Outperform	Raymond James
5/1/2024	$90.00 → $85.00	Buy	Maxim Group

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

Chat with this insight

Recent Analyst Ratings for $GILD

$GILD Market Insights

Live Market Insights

This Is What Whales Are Betting On Gilead Sciences

Gilead Sciences shares are trading higher after the company announced new 5-year data reinforcing Biktarvy as a long term HIV treatment.

Gilead Sciences Presents New 5-Year Data Reinforcing Biktarvy As Long-Term HIV Treatment; Investigational Dosing Frequencies Aim To Expand Options And Address Unmet Needs; Key Findings Presented At AIDS 2024 Conference Highlight Innovative HIV Treatment Portfolio And Research Pipeline

$GILD Press Releases

Fastest customizable press release news feed in the world

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Sciences to Present at Upcoming Investor Engagements

$GILD SEC Filings

Gilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by Gilead Sciences Inc.

SEC Form FWP filed by Gilead Sciences Inc.

$GILD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$GILD Financials

Live finance-specific insights

$GILD Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GILD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$GILD Leadership Updates

Live Leadership Updates

$GILD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chief Commercial Officer Mercier Johanna sold $456,400 worth of shares (5,000 units at $91.28), decreasing direct ownership by 6% to 73,127 units (SEC Form 4)

Chief Medical Officer Parsey Merdad exercised 25,000 shares at a strike of $57.92 and sold $2,341,485 worth of shares (25,590 units at $91.50), decreasing direct ownership by 0.59% to 99,599 units (SEC Form 4)

EVP, Corporate Affairs & GC Telman Deborah H converted options into 514 shares and covered exercise/tax liability with 242 shares, increasing direct ownership by 1% to 20,979 units (SEC Form 4)

Gilead Sciences Announces Third Quarter 2024 Financial Results

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Gilead Sciences Announces Second Quarter 2024 Financial Results

SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

SEC Form SC 13G filed by Gilead Sciences Inc.

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors

Wolfe Research initiated coverage on Gilead Sciences with a new price target

Citigroup initiated coverage on Gilead Sciences with a new price target

Gilead Sciences downgraded by Maxim Group

$GILD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

Recent Analyst Ratings for
$GILD

$GILD
Market Insights

$GILD
Press Releases

$GILD
SEC Filings

$GILD
Insider Trading

$GILD
Financials

$GILD
Large Ownership Changes

$GILD
FDA approvals

$GILD
Leadership Updates

$GILD
Analyst Ratings

$GILD
Insider Purchases